| ☆ | Note : les références [85Chocry M, ICO, Nantes Université, CNRS, US2B, UMR 6286, DNA-repair Group, Nantes, France. Induced radioresistance following communication of pericytes and vascular endothelial cells with glioblastoma cancer cells.
Cliccare qui per andare alla sezione Riferimenti, 15Deutsch E, Department of Oncology and Radiotherapy, Institut Gustave-Roussy Paris, France. Dose distribution, rate and volumes in radiotherapy, preclinical data and new conceptsj.bulcan.2023.08.007
Cliccare qui per andare alla sezione Riferimenti, 19Beaufils V, Université de Caen-Normandie, CNRS, Normandie Univ, ISTCT UMR6030, GIP Cyceron, Caen, France. Optimisation study of a whole-brain irradiation model in the rat: comparison between vertical and horizontal X-ray beams.
Cliccare qui per andare alla sezione Riferimenti, 20Bogaerts E, Department of Oncology, KU Leuven, Leuven & Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Woluwé-Saint-Lambert, Belgium. Proton irradiation at ultra-high-dose-rate results in lower induction of radiation-responsive genes in zebrafish embryos.
Cliccare qui per andare alla sezione Riferimenti, 24Simonin G, Institut Pluridisciplinaire Hubert-Curien, UMR 7178, Strasbourg, France. Towards FLASH dosimetry on PRECy platform.
Cliccare qui per andare alla sezione Riferimenti, 25Daviau G, Grand accélérateur National d’Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France. Development of a new high spatial and temporal resolution scintillating dosimeter.
Cliccare qui per andare alla sezione Riferimenti, 26Bodenstein E, OncoRay, National Center for Radiation Research in Oncology - Faculty of Medicine and University, Hospital Carl Gustav Carus-Technische Universitat Dresden-Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. Proton radiography used for high precision small animal irradiation at ultra-high dose rates.
Cliccare qui per andare alla sezione Riferimenti, 27Evin M, Nantes Université, IMT Atlantique, CNRS/IN2P3, SUBATECH, Nantes, France. Dosimetric environment and first results of the studies on the physicochemical and biological mechanisms of FLASH hadrontherapy at the ARRONAX cyclotron.
Cliccare qui per andare alla sezione Riferimenti, 28Holland J-P, Department of Chemistry, University of Zürich, Switzerland. New tactics in the design of radiotheranostics.
Cliccare qui per andare alla sezione Riferimenti, 30Mari M, Department of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy. Coumarin derivatives for MCT1 targeting in nuclear medicine: from fluorine to copper.
Cliccare qui per andare alla sezione Riferimenti, 31Santos L, CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, Portugal. Therapeutic Efficacy of [177Lu]Lu-DOTA-Trastuzumab in Trastuzumab-resistant HER2-Positive metastatic lesions.
Cliccare qui per andare alla sezione Riferimenti, 33Genz J, University of Zurich, Zurich, Switzerland. Matched Pair Theranostics with 99mTc and 188Re-DETA-N-Onartuzumab for the Hepatocyte Growth Factor Receptor.
Cliccare qui per andare alla sezione Riferimenti, 40Hollenstein M, Institut Pasteur, Department of Structural Biology and Chemistry, Laboratory for Bioorganic Chemistry of Nucleic Acids, CNRS UMR3523, Paris, France. Nucleic acids as tools for the treatment and diagnostics of cancer.
Cliccare qui per andare alla sezione Riferimenti, 43Petitpoisson L, Équipe de Synthèse pour l’Analyse, Université de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France. Tb(III) octadentate bispidine-based complexes for potential application in radiotherapy and theragnostic imaging.
Cliccare qui per andare alla sezione Riferimenti, 44Csupász T, University of Debrecen, Faculty of Science and Technology, Institute of Chemistry - Department of Physical Chemistry, Debrecen, Hungary. Synthesis and characterization of hypoxia-sensitive 44Sc(III) and 52Mn(II) macrocyclic complexes for their application in PET imaging.
Cliccare qui per andare alla sezione Riferimenti, 45Loubières A, Laboratoire CEMCA UMR CNRS 6521, Brest, France. Zr(IV): a metal of choice for innovative diagnostic methods.
Cliccare qui per andare alla sezione Riferimenti, 46Battistin F, Department of Chemistry, University of Zurich, Zurich, Switzerland. 99mTc(η6-pharm)2+ synthesis with direct labelling of pharmaceuticals in water.
Cliccare qui per andare alla sezione Riferimenti, 48Laurent N, CRCI2NA, UMR 1307 CNRS 6075 NU, Nantes, France. Overview of circulating tumor cells heterogeneity for targeted alpha therapy.
Cliccare qui per andare alla sezione Riferimenti, 49Santos JF, C2TN Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, U. Lisboa, Portugal. Dual-targeted 111In- and 161Tb-Radiocomplexes for Prostate Cancer Theranostics.
Cliccare qui per andare alla sezione Riferimenti, 50Ferreira NH, Nantes - Angers Cancer and Immunology Research Center, University of Angers, SFR ICAT, Angers, France. Implantable silk-fibroin hyaluronic-acid scaffold into resection cavities: modifying glioblastoma ecosystem dynamics to enhance efficacy of radiotherapy.
Cliccare qui per andare alla sezione Riferimenti, 51Bert J, LaTIM, National Institute of Health & Clinical Sciences, Brest University, France. AI dose calculation: application in radiation and radionuclide therapies.
Cliccare qui per andare alla sezione Riferimenti, 52Diaz Hernandez KV, Science Faculty, University of Zürich, Zürich, Switzerland. Fitting of novel analytical population tumor control probability model to NSCLC data.
Cliccare qui per andare alla sezione Riferimenti, 54Ryhiner M, Department of Nuclear Medicine, Inselspital, University of Bern, Switzerland. Simulating quantitative PARPi radiosensitization of BRCA deficient cancer cells during radiopharmaceutical therapies.
Cliccare qui per andare alla sezione Riferimenti, 57Bert J, LaTIM, National Institute of Health & Clinical Sciences, Brest University, France. AI dose calculation: application in radiation and radionuclide therapies.
Cliccare qui per andare alla sezione Riferimenti, 58Rios Sanchez E, Creatis, Lyon & Siemens Healthcare SAS, Paris, France. 68Ga-PSMA PET/CT imaging features with PSA variation for castration-resistant prostate cancer patients.
Cliccare qui per andare alla sezione Riferimenti, 59Giraud P, Radiation Oncology, Hôpital Pitié-Salpêtrière, Paris, France. External validation of a predictive model for severe malnutrition trained on a multicentric real-life cohort from UNITRAD.
Cliccare qui per andare alla sezione Riferimenti, 64Baffroy O, Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université de Bourgogne, Dijon, France. Toward water-soluble gold-based Aza-BODIPY theranostic.
Cliccare qui per andare alla sezione Riferimenti, 65Godard A, Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université de Bourgogne, Dijon, France. NIR-II aza-BODIPYs, a new family of contrast agents for fluorescence-guided surgery of cancers.
Cliccare qui per andare alla sezione Riferimenti, 68Jiménez-Sánchez J, Mathematical Oncology Laboratory (MOLAB), University of Castilla-La Mancha (UCLM), Ciudad Real, Spain. Chemo-radiotherapy optimization in gliomas: discrete models and virtual clinical trials.
Cliccare qui per andare alla sezione Riferimenti, 69Mondino A, Head of Lymphocyte Activation Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Prostate-confined radiotherapy to empower TCR/CAR T cells against primary and metastatic prostate adenocarcinoma.
Cliccare qui per andare alla sezione Riferimenti, 72Jacquet C, CRCI2NA, UMR 1307 CNRS 6075 NU, Nantes, France. Radiobiology of alpha-particles: immunogenicity of anti-tumor targeted-alpha therapy in mouse models.
Cliccare qui per andare alla sezione Riferimenti, 74Bargh-Dawson H, Institute of Cancer Research, London, United Kingdom. Evaluation of murine head and neck carcinoma models for determining response to ultrasound-stimulated microbubbles combined with radiotherapy.
Cliccare qui per andare alla sezione Riferimenti, 76Stelse-Masson S, Institute for Advanced Biosciences, INSERM, CNRS & Synchrotron Radiation for Biomedicine, Université Grenoble Alpes, Grenoble, France. Scintillating nanoparticles to induce radiation dose-enhancement and X-PDT for pancreatic cancer.
Cliccare qui per andare alla sezione Riferimenti, 78Lopes FAC, Physics Centre of Minho and Porto Universities (CF-UM-UP), University of Minho, Braga, Portugal. Development of multifunctional liposomes containing magnetic/gold nanoparticles for combination cancer therapies.
Cliccare qui per andare alla sezione Riferimenti, 79Rinaldi A, Nantes - Angers Cancer and Immunology Research Center, University of Angers, SFR ICAT, Angers, France. Polymer-lipid Hybrid Nanomedicines for siRNA Delivery Against Glioblastoma.
Cliccare qui per andare alla sezione Riferimenti, 81Coppes R, Department of Biomedical Sciences of Cells & Systems & Department of Radiation Oncology, University Medical Center Groningen & University of Groningen, Groningen, The Netherlands. The use of organoids in radiotherapy research; mechanisms, prediction and regeneration.
Cliccare qui per andare alla sezione Riferimenti, 82Dubail M, Institut Curie, Inserm U1021-CNRS UMR 3347, University Paris-Saclay, PSL Research University, Centre Universitaire, Orsay, France. Development of an ex vivo assay enabling rapid quantification of radiotherapy induced toxicities in healthy lung.
Cliccare qui per andare alla sezione Riferimenti, 84Passerat de la Chapelle E, Space Biosciences Division, NASA Ames Research Center & Blue Marble Space Institute of Science & Nantes University, Nantes, France. Neurovascular responses to ionizing radiation in a human organ-on-a-chip model.
Cliccare qui per andare alla sezione Riferimenti] se rapportent aux titres des communications orales effectuées lors du workshop.
|
, Vincent Potiron 2, 3, Nicolas Lepareur 4, Latifa Rbah-Vidal 5, Emmanuel Garcion 6, Florence Dumas 6, Michel Chérel 5, Raphaël Tripier 7, Jacques Barbet 8
Articolo precedente
